315 related articles for article (PubMed ID: 25312044)
1. Malignancy risk in patients with inflammatory eye disease treated with systemic immunosuppressive therapy: a tertiary referral cohort study.
Yates WB; Vajdic CM; Na R; McCluskey PJ; Wakefield D
Ophthalmology; 2015 Feb; 122(2):265-73. PubMed ID: 25312044
[TBL] [Abstract][Full Text] [Related]
2. Analysis of a novel protocol of pulsed intravenous cyclophosphamide for recalcitrant or severe ocular inflammatory disease.
Suelves AM; Arcinue CA; González-Martín JM; Kruh JN; Foster CS
Ophthalmology; 2013 Jun; 120(6):1201-9. PubMed ID: 23601800
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil therapy for inflammatory eye disease.
Thorne JE; Jabs DA; Qazi FA; Nguyen QD; Kempen JH; Dunn JP
Ophthalmology; 2005 Aug; 112(8):1472-7. PubMed ID: 16061096
[TBL] [Abstract][Full Text] [Related]
4. Risk of corticosteroid-induced hyperglycemia requiring medical therapy among patients with inflammatory eye diseases.
Udoetuk JD; Dai Y; Ying GS; Daniel E; Gangaputra S; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Kempen JH;
Ophthalmology; 2012 Aug; 119(8):1569-74. PubMed ID: 22484116
[TBL] [Abstract][Full Text] [Related]
5. Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy.
Thorne JE; Woreta FA; Jabs DA; Anhalt GJ
Ophthalmology; 2008 Dec; 115(12):2146-2152.e1. PubMed ID: 18930554
[TBL] [Abstract][Full Text] [Related]
6. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study.
Tessari G; Naldi L; Boschiero L; Nacchia F; Fior F; Forni A; Rugiu C; Faggian G; Sassi F; Gotti E; Fiocchi R; Talamini G; Girolomoni G
Arch Dermatol; 2010 Mar; 146(3):294-9. PubMed ID: 20231501
[TBL] [Abstract][Full Text] [Related]
7. Azathioprine for ocular inflammatory diseases.
Pasadhika S; Kempen JH; Newcomb CW; Liesegang TL; Pujari SS; Rosenbaum JT; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Suhler EB
Am J Ophthalmol; 2009 Oct; 148(4):500-509.e2. PubMed ID: 19570522
[TBL] [Abstract][Full Text] [Related]
8. Long-term progression, prognosis, and treatment of patients with recurrent ocular manifestations of Reiter's syndrome.
Kiss S; Letko E; Qamruddin S; Baltatzis S; Foster CS
Ophthalmology; 2003 Sep; 110(9):1764-9. PubMed ID: 13129875
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide for ocular inflammatory diseases.
Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate for ocular inflammatory diseases.
Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
[TBL] [Abstract][Full Text] [Related]
11. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.
Asgari MM; Ray GT; Geier JL; Quesenberry CP
J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854
[TBL] [Abstract][Full Text] [Related]
12. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis.
Faurschou M; Mellemkjaer L; Voss A; Keller KK; Hansen IT; Baslund B
Rheumatology (Oxford); 2015 Aug; 54(8):1345-50. PubMed ID: 25234661
[TBL] [Abstract][Full Text] [Related]
13. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
14. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
[TBL] [Abstract][Full Text] [Related]
15. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation.
Galor A; Jabs DA; Leder HA; Kedhar SR; Dunn JP; Peters GB; Thorne JE
Ophthalmology; 2008 Oct; 115(10):1826-32. PubMed ID: 18579209
[TBL] [Abstract][Full Text] [Related]
16. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.
Long A; Rahmaoui A; Rothman KJ; Guinan E; Eisner M; Bradley MS; Iribarren C; Chen H; Carrigan G; Rosén K; Szefler SJ
J Allergy Clin Immunol; 2014 Sep; 134(3):560-567.e4. PubMed ID: 24679845
[TBL] [Abstract][Full Text] [Related]
17. Scleritis therapy.
Sainz de la Maza M; Molina N; Gonzalez-Gonzalez LA; Doctor PP; Tauber J; Foster CS
Ophthalmology; 2012 Jan; 119(1):51-8. PubMed ID: 22015381
[TBL] [Abstract][Full Text] [Related]
18. Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.
Geusau A; Dunkler D; Messeritsch E; Sandor N; Heidler G; Rödler S; Ankersmit J; Zuckermann A; Tschachler E
Int J Dermatol; 2008 Sep; 47(9):918-25. PubMed ID: 18937654
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil for ocular inflammation.
Daniel E; Thorne JE; Newcomb CW; Pujari SS; Kaçmaz RO; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Foster CS; Jabs DA; Kempen JH
Am J Ophthalmol; 2010 Mar; 149(3):423-32.e1-2. PubMed ID: 20042178
[TBL] [Abstract][Full Text] [Related]
20. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort.
Dreyer L; Faurschou M; Mogensen M; Jacobsen S
Arthritis Rheum; 2011 Oct; 63(10):3032-7. PubMed ID: 21953088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
